STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Coastlands Reports 2.82M Shares, 5.98% of WHWK Common Stock

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Coastlands-related parties report beneficial ownership of 2,819,215 shares of Whitehawk Therapeutics common stock, representing 5.98% of the outstanding shares based on 47,128,362 shares cited as of August 4, 2025. The holdings are reported across Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Matthew D. Perry. Voting and dispositive power is reported as shared for most entities, with Coastlands Capital GP LLC showing sole voting and dispositive power in one cover-sheet entry, while other reporting persons indicate shared power. The filing states the securities were acquired and are held in the ordinary course of business and are not intended to change or influence control of the issuer.

Positive

  • Material ownership disclosed: Reporting persons own 2,819,215 shares, equating to 5.98% of the class, enhancing market transparency.
  • Clear attribution across entities: The filing identifies the adviser, partnership, general partner and control person, clarifying ownership relationships.
  • Passive intent declared: The securities are stated to be held in the ordinary course of business and not to effect control, consistent with Schedule 13G treatment.

Negative

  • None.

Insights

TL;DR A single investor group holds just under 6% of WHWK, disclosed as shared ownership and presented as passive in intent.

The Schedule 13G shows a 5.98% ownership stake, large enough to trigger disclosure but below typical activist thresholds. The split of voting and dispositive power across affiliated entities suggests centralized control through the general partner structure while maintaining adviser/partnership distinctions. This is a routine, material ownership disclosure that increases investor transparency but does not by itself indicate a change in strategic direction or control.

TL;DR Reporting structure indicates coordinated ownership via adviser and GP, disclosed as not seeking control.

The filing clarifies roles: the partnership holds the shares for investors, the adviser and GP exercise reported powers, and the named individual is the control person of the related entities. The certification that the position is held in the ordinary course and not for control is typical for a Schedule 13G. Governance implications are limited absent further accumulations or coordination with other investors.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 47,128,362 shares of Common Stock outstanding on August 4, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 47,128,362 shares of Common Stock outstanding on August 4, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 47,128,362 shares of Common Stock outstanding on August 4, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 47,128,362 shares of Common Stock outstanding on August 4, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Percentage calculated based on 47,128,362 shares of Common Stock outstanding on August 4, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025.


SCHEDULE 13G



Coastlands Capital LP
Signature:/s/ Mark Shamia
Name/Title:Chief Operating Officer of the General Partner, Coastlands Capital LLC
Date:08/25/2025
Coastlands Capital Partners LP
Signature:/s/ Mark Shamia
Name/Title:Chief Operating Officer of the General Partners, Coastlands Capital GP LLC
Date:08/25/2025
Coastlands Capital GP LLC
Signature:/s/ Mark Shamia
Name/Title:Chief Operating Officer
Date:08/25/2025
Coastlands Capital LLC
Signature:/s/ Mark Shamia
Name/Title:Chief Operating Officer
Date:08/25/2025
Matthew D. Perry
Signature:/s/ Matthew D. Perry
Name/Title:Reporting Person
Date:08/25/2025

FAQ

How many Whitehawk Therapeutics (WHWK) shares do Coastlands reporting persons own?

They report beneficial ownership of 2,819,215 shares, equal to 5.98% of outstanding common stock as of August 4, 2025.

Does the Schedule 13G indicate Coastlands intends to take control of WHWK?

No. The filing certifies the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Which Coastlands entities are named on the filing for WHWK?

The filing names Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Matthew D. Perry.

What type of voting and dispositive power is reported for these shares?

Most reporting persons indicate shared voting and shared dispositive power over the 2,819,215 shares; one cover entry lists sole power for the GP entity.

On what share count is the 5.98% ownership percentage based?

The percentage is calculated using 47,128,362 shares of common stock outstanding as of August 4, 2025, per the issuer's referenced filing.
Whitehawk Therapeutics Inc

NASDAQ:WHWK

WHWK Rankings

WHWK Latest News

WHWK Latest SEC Filings

WHWK Stock Data

120.65M
37.10M
12.43%
68.55%
0.51%
Biotechnology
Pharmaceutical Preparations
Link
United States
MORRISTOWN